睿知中国医院研究地图
候选清单

即将招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC

ClinicalTrials.gov 上登记的一项肺癌开放试验,由北京大学人民医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京大学人民医院Peking University People's Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07885709,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Previously untreated, histologically confirmed, resectable or borderline resectable stage II-IIIA or IIIB (N2) non-small cell lung cancer, per the 8th edition AJCC staging.

    入选标准第 2 条

  3. Women of childbearing potential must have a negative serum pregnancy test within 3 days prior to enrollment and agree to use effective contraception during study treatment and for 120 days after the last dose. Women of childbearing potential are defined as sexually mature women who (1) have not undergone hysterectomy or bilateral oophorectomy and (2) have not been naturally postmenopausal for 12 consecutive months (cancer-therapy-related amenorrhea does not preclude childbearing potential).

    入选标准第 13 条

    Active hepatitis B or C requiring antiviral therapy; patients with hepatitis B must have HBV-DNA <500 IU/mL and have received at least 14 days of anti-HBV therapy prior to enrollment, with treatment continued during the study; patients with positive HCV RNA are excluded.

    排除标准第 2 条

    Major surgery within 4 weeks prior to enrollment (excluding minimally invasive diagnostic procedures such as diagnostic biopsy, percutaneous lung puncture, EBUS-TBNA, or central venous catheterization), or presence of an unhealed surgical incision, ulcer, or fracture.

    排除标准第 12 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

    入选标准第 6 条

  5. Presence of at least one measurable lesion per RECIST 1.1.

    入选标准第 12 条

  6. Pregnancy or breastfeeding.

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07885709,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary participation with signed informed consent.
  2. Previously untreated, histologically confirmed, resectable or borderline resectable stage II-IIIA or IIIB (N2) non-small cell lung cancer, per the 8th edition AJCC staging.
  3. Negative for EGFR and ALK driver alterations, confirmed by next-generation sequencing (NGS) or RT-PCR on tumor tissue; blood-based NGS permitted when tissue is insufficient.
  4. Sufficient tumor tissue for PD-L1 immunohistochemistry and NGS testing, with baseline tissue reserved for construction of a tumor-informed, fixed panel for subsequent MRD detection.
  5. Age ≥18 years, either sex.
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  7. Adequate cardiac function with left ventricular ejection fraction (LVEF) >50%.
  8. Adequate pulmonary function (FEV1 >1.5 L and DLCO >50%) to tolerate definitive lung cancer resection.
  9. Adequate bone marrow function: white blood cell count >4×10⁹/L, neutrophil count >1.5×10⁹/L, hemoglobin >10 g/dL, and platelet count >100×10⁹/L.
  10. Adequate renal function with glomerular filtration rate >60 mL/min.
  11. Adequate hepatic function: total bilirubin <1.5× upper limit of normal (ULN), aspartate aminotransferase (AST) <3× ULN, and alanine aminotransferase (ALT) <3× ULN.
  12. Presence of at least one measurable lesion per RECIST 1.1.
  13. Women of childbearing potential must have a negative serum pregnancy test within 3 days prior to enrollment and agree to use effective contraception during study treatment and for 120 days after the last dose. Women of childbearing potential are defined as sexually mature women who (1) have not undergone hysterectomy or bilateral oophorectomy and (2) have not been naturally postmenopausal for 12 consecutive months (cancer-therapy-related amenorrhea does not preclude childbearing potential).

排除标准:Exclusion Criteria:

  1. Active autoimmune disease or a history of autoimmune disease that may recur, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease (adequately controlled hypothyroidism on stable hormone replacement may be permitted), type 1 diabetes mellitus, multiple sclerosis, vasculitis, or glomerulonephritis.
  2. Active hepatitis B or C requiring antiviral therapy; patients with hepatitis B must have HBV-DNA <500 IU/mL and have received at least 14 days of anti-HBV therapy prior to enrollment, with treatment continued during the study; patients with positive HCV RNA are excluded.
  3. Known allergy to carboplatin, paclitaxel, nab-paclitaxel, pemetrexed, or other chemotherapeutic agents.
  4. History of allergy to monoclonal antibody drugs.
  5. Known allergy to anlotinib or any of its excipients.
  6. Prior allogeneic stem cell or solid organ transplantation.
  7. Severe or active infection requiring systemic therapy within 4 weeks prior to enrollment, including but not limited to active pulmonary tuberculosis, bacterial infection requiring intravenous antibiotics, active fungal infection, or known human immunodeficiency virus (HIV) infection (HIV antibody positive).
  8. Psychiatric disorders or any other condition that would preclude compliance with treatment.
  9. Inability or unwillingness to provide signed informed consent.
  10. Severe cardiovascular disease, including but not limited to: myocardial infarction, unstable angina, cerebrovascular accident (cerebral infarction or hemorrhage), or transient ischemic attack within 6 months prior to enrollment; New York Heart Association (NYHA) class ≥2 congestive heart failure; severe arrhythmia requiring medication (e.g., sustained ventricular tachycardia, or atrial fibrillation with rapid ventricular rate poorly controlled by medication); uncontrolled hypertension (systolic ≥150 mmHg and/or diastolic ≥95 mmHg) despite standard antihypertensive treatment; congenital long QT syndrome, or prolonged Fridericia-corrected QT interval (QTcF) on screening (males >450 ms, females >470 ms).
  11. Clinically significant bleeding risk or coagulation abnormality, including: known bleeding diathesis (e.g., hemophilia, von Willebrand disease) or hereditary coagulation disorders; grade ≥2 hemoptysis (single episode ≥2.5 mL) or grade ≥3 bleeding at other sites within 3 months prior to enrollment; clinically significant gastrointestinal bleeding within 4 weeks prior to enrollment; ongoing full-dose anticoagulation (e.g., warfarin, heparins, direct oral anticoagulants) that cannot be suspended or bridged to low-molecular-weight heparin during the study (patients on prophylactic low-dose anticoagulation may be eligible per investigator judgment); use of aspirin (>325 mg/day) or other platelet-inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs) within 10 days prior to enrollment; imaging showing tumor invasion of or proximity to a major vessel with investigator-assessed bleeding risk.
  12. Major surgery within 4 weeks prior to enrollment (excluding minimally invasive diagnostic procedures such as diagnostic biopsy, percutaneous lung puncture, EBUS-TBNA, or central venous catheterization), or presence of an unhealed surgical incision, ulcer, or fracture.
  13. Pregnancy or breastfeeding.
  14. Prior or concurrent other malignancy (cured low-risk tumors such as basal cell carcinoma, squamous cell carcinoma of the skin, cervical carcinoma in situ, or papillary thyroid carcinoma may be enrolled if, per investigator judgment, they do not affect efficacy or safety evaluation).
  15. Known active or uncontrolled interstitial lung disease (ILD) or pulmonary fibrosis, or screening imaging suggestive of ILD/non-infectious pneumonitis requiring corticosteroids, or a history of ILD/non-infectious pneumonitis requiring corticosteroid treatment.
  16. Receipt of a live or live-attenuated vaccine within 30 days prior to enrollment.
  17. Any comorbidity or other condition that, in the investigator's judgment, may affect protocol compliance or render the patient unsuitable for participation.

引自 ClinicalTrials.gov, NCT07885709, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07885709,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07885709